2020 官网升级中！现在您访问官网的浏览器设备分辨率宽度低于1280px请使用高分辨率宽度访问。
Disease Area
Product
Modality
Target
Discovery
IND
Ph I
Ph II
PhIII/Pivotal
BLA
Approval
Anruize®
1.Herceptin (Trastuzumab) biosimilar
2.Launched in 2023, the cornerstone drug for HER2+ BC treatment
3.The results of the Ph3 clinical trial indicated that Anruize is highly similar to the original drug Herceptin in terms of clinical efficacy, safety, pharmacokinetics, and immunogenicity
4.Anruize originates from Trastuzumab’s international standard collaborative calibration unit, bringing new high-quality options for clinical anti-HER2 treatment
mAb
Her2
Anruixi®
China's first CD20 antibody class I innovative drug. A human-mouse chimeric monoclonal antibody targeting CD20 on the surface of B-cell, leading to B-cell elimination via ADCC and CDC effect. Compared with other anti-CD20 mAbs, HS006 has stronger ADCC effect and volume of distribution at steady state (Vss), which leads to prolongated B-cell elimination and better efficacy
mAb
CD-20
HS627
Bosimilar of Pertuzumab
mAb
Her2
BR105
(lumistobart)
A humanized monoclonal antibody targeting macrophage checkpoint SIRPα. BR105 can bind with all common variants of SIRPα and block their interaction with CD47 (the "don't-eat-me" signaling pathway), releasing the break of macrophage anti-tumor activity. BR105 has demonstrated synergistic effect with various anti-TAA therapies in preclinical studies.
mAb
SIRPα
BR105
(lumistobart)
A humanized monoclonal antibody targeting macrophage checkpoint SIRPα. BR105 can bind with all common variants of SIRPα and block their interaction with CD47 (the "don't-eat-me" signaling pathway), releasing the break of macrophage anti-tumor activity. BR105 has demonstrated synergistic effect with various anti-TAA therapies in preclinical studies.
mAb
SIRPα
BR110
A tri-specific antibody that simultaneously targets CD3 on T-cell and CD20/CD19 on tumor cell, thus killing CD20/CD19 expressing tumor cell by recruiting T-cell.
Tri-specific
CD3/CD19/CD20
BR101
(ansipastobart)
A monoclonal antibody that recognizes a specific epitope of CD73. BR101 can block the enzymatic activity of membrane and soluble CD73 non-competitively, decreasing the formation of immune-suppressive adenosine in tumor micro-environment. in complement with its enzyme-mediated effect, BR101 can also significantly decrease the expression of CD73 on cell surface.
mAb
CD73
BR108
An ADCC-enhanced monoclonal antibody targeting CD70. BR108 demonstrated superior binding affinity to CD70, and could effectively kill various types of CD70 expressing tumor cells via ADCC, ADCP and CDC in preclinical studies.
mAb
Undisclosed
BRY805
A humanized monoclonal antibody targeting C-type lectin-like type II transmembrane protein NKG2A. By blocking the interaction between NKG2A and HLA-E, BRY805 demonstrated anti-tumor activity by releasing the break on Natural-killer (NK) cell.
mAb
NKG2A
BR109
Target undisclosed
ADC/bi-specific
Undisclosed
BR115
A T-cell engaged tri-specific antibody for solid tumor
Tri-specific
CD3/Her2/Her2
BRY812
A LIV-1 targeted ADC with small-molecule toxins linked via CysLink™ irreversible chemistry conjugation platform and a highly stable linker. By binding to LIV-1 on the surface of tumor cells, the ADC-target complex enters the tumor cell’s lysosome through endocytosis, releasing small molecule toxins that selectively kill tumor cells.
ADC
LIV-1
TO TOP
